Anthrax infection

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 12, 2011, Pages 1333-1341

  Sweeney, Daniel A ^a   Hicks, Caitlin W ^b   Cui, Xizhong ^c   Li, Yan ^c   Eichacker, Peter Q ^c  

^a Washington Hospital   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bacillus anthracis; Diagnosis; Pathogenesis; Treatment

Indexed keywords

ANTHRAX TOXIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINDAMYCIN; DIAMORPHINE; DOXYCYCLINE; EUROPIUM; MEROPENEM; PENICILLIN G; PROTEINASE; RIFAMPICIN;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL MEMBRANE; BACTERIAL SPORE; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BODY TEMPERATURE; CELL WALL; CHILL; COUGHING; DIAGNOSTIC PROCEDURE; DYSPNEA; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEVER; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INFECTION CONTROL; INHALATIONAL ANTHRAX; MALAISE; MICROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SHOCK; SKIN ANTHRAX; SKIN INFECTION; SOFT TISSUE INFECTION; TACHYCARDIA;

ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BIOTERRORISM; GASTROINTESTINAL DISEASES; HUMANS; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES, BACTERIAL; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84455207436     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201102-0209CI     Document Type: Review

References (85)

1. Wenner KA, Kenner JR. Anthrax. Dermatol Clin 2004;22:247-256. (Pubitemid 38781721)
2. Carr KA, Lybarger SR, Anderson EC, Janes BK, Hanna PC. The role of bacillus anthracis germinant receptors in germination and virulence. Mol Microbiol 2010;75:365-375.
3. Hanna P. Anthrax pathogenesis and host response. Curr Top Microbiol Immunol 1998;225:13-35. (Pubitemid 27448604)
4. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, et al. Biodefense WGoC. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287:2236-2252. (Pubitemid 34441940)
5. Friedlander AM. Tackling anthrax. Nature 2001;414:160-161.
6. Makino S, Uchida I, Terakado N, Sasakawa C, Yoshikawa M. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in bacillus anthracis. J Bacteriol 1989;171:722-730. (Pubitemid 19053478)
7. Turk BE. Manipulation of host signalling pathways by anthrax toxins. Biochem J 2007;402:405-417. (Pubitemid 46423878)
8. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic amp concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982;79:3162-3166. (Pubitemid 12008374)
9. Moayeri M, Leppla SH. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med 2009;30:439-455.
10. Sherer K, Li Y, Cui X, Eichacker PQ. Lethal and edema toxins in the pathogenesis of bacillus anthracis septic shock: implications for therapy. Am J Respir Crit Care Med 2007;175:211-221. (Pubitemid 46203123)
11. Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA. Inhalational anthrax: epidemiology, diagnosis, and management. Chest 1999;116:1369-1376. (Pubitemid 29535995)
12. Demirdag K, Ozden M, Saral Y, Kalkan A, Kilic SS, Ozdarendeli A. Cutaneous anthrax in adults: a review of 25 cases in the eastern Anatolian region of Turkey. Infection 2003;31:327-330. (Pubitemid 37260368)
13. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002;8:1019-1028. (Pubitemid 35256987)
14. Gold H. Anthrax: a report of one hundred seventeen cases. AMA Arch Intern Med 1955;96:387-396.
15. Doganay M, Metan G, Alp E. A review of cutaneous anthrax and its outcome. J Infect Public Health 2010;3:98-105.
16. Centers for Disease Control and Prevention (CDC). Emergency preparedness and response: specific hazards: bioterrorism: anthrax: gastrointestinal anthrax [Internet] [accessed 2011 June 13]. Available from: http://www.bt.cdc.gov/agent/ anthrax/gi/.
17. Kanafani ZA, Ghossain A, Sharara AI, Hatem JM, Kanj SS. Endemic gastrointestinal anthrax in 1960s Lebanon: clinical manifestations and surgical findings. Emerg Infect Dis 2003;9:520-525. (Pubitemid 36529508)
18. Centers for Disease Control and Prevention (CDC). Gastrointestinal anthrax after an animal-hide drumming event: New Hampshire and Massachusetts, 2009. MMWR Morb Mortal Wkly Rep 2010;59:872-877.
19. Klempner MS, Talbot EA, Lee SI, Zaki S, Ferraro MJ. Case records of the Massachusetts General Hospital. Case 25-2010: a 24-year-old woman with abdominal pain and shock. N Engl J Med 2010;363:766-777.
20. Sirisanthana T, Brown AE. Anthrax of the gastrointestinal tract. Emerg Infect Dis 2002;8:649-651. (Pubitemid 34764726)
21. Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980;353:83-93. (Pubitemid 11185050)
22. Plotkin SA, Brachman PS, Utell M, Bumford FH, Atchison MM. An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features. Am J Med 1960;29:992-1001.
23. Health protection report: a single case of inhalation anthrax in a drum maker in London [accessed 2011 June 13]. Available from: http://www.hpa.org.uk/ hpr/archives/2008/news4408.htm.
24. Suffin SC, Carnes WH, Kaufmann AF. Inhalation anthrax in a home craftsman. Hum Pathol 1978;9:594-597. (Pubitemid 9079119)
25. Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, Guarner J, Wilkins P, Norville KJ, Barr JR, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin g and lethal factor. Clin Infect Dis 2007;44:968-971. (Pubitemid 46452063)
26. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 1993;90:2291-2294. (Pubitemid 23078612)
27. Kyriacou DN, Stein AC, Yarnold PR, Courtney DM, Nelson RR, Noskin GA, Handler JA, Frerichs RR. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004;364:449-452. (Pubitemid 39036893)
28. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006;144:270-280. (Pubitemid 46768211)
29. Ross J. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 1957;73:485-494.
30. Ringertz SH, Høiby EA, Jensenius M, Maehlen J, Caugant DA, Myklebust A, Fossum K. Injectional anthrax in a heroin skin-popper. Lancet 2000;356:1574-1575.
31. Final tally of anthrax cases announced. December 23, 2010: Health Protection Scotland; 2010 [accessed September 29, 2011]. Available from: http://www.hps.scot.nhs.uk/news/spdetail.aspex?id=370.
32. Anthrax confirmed in an injecting drug user in Kent. November 3, 2010: The Health Protection Agency; 2010 [accessed September 29, 2011]. Available from: http://www.hpa.org.uk/ProductsServices/LocalServices/SouhtEast/SouhtEast.
33. UK investigators puzzled by anthrax outbreak. Friday 24 September 2010 [accessed March 15, 2011]. Available from: http://www.eht-forum.org/news.html? targetPage=news/fulltext/news100924022146.html&from=search.
34. Radun D, Bernard H, Altmann M, Schöneberg I, Bochat V, van Treeck U, Rippe RM, Grunow R, Elschner M, Biederbick W, et al. Preliminary case report of fatal anthrax in an injecting drug user in North-Rhine-Westphalia, Germany, December 2009. Euro Surveill 2010;15:19464.
35. Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol 2004;150:1-10. (Pubitemid 38234002)
36. United States Central Intelligence Agency. The world factbook: field listing: Illicit drugs [accessed 2011 June 13]. Available from: https://www.cia.gov/library/publications/the-world-factbook/fields/2086.html.
37. Moustoukas NM, Nichols RL, Smith JW, Garey RE, Egan RR. Contaminated street heroin: relationship to clinical infections. Arch Surg 1983;118:746-749. (Pubitemid 13093322)
38. Booth MG, Hood J, Brooks TJ, Hart A. Network obot HPSAC. Anthrax infection in drug users. Lancet 2011;375:1345-1346.
39. Doganay M, Bakir M, Dokmetas I. A case of cutaneous anthrax with toxaemic shock. Br J Dermatol 1987;117:659-662. (Pubitemid 18080135)
40. Kuehnert MJ, Doyle TJ, Hill HA, Bridges CB, Jernigan JA, Dull PM, Reissman DB, Ashford DA, Jernigan DB. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis 2003;36:328-336. (Pubitemid 36169669)
41. Cui X, Moayeri M, Li Y, Li X, Haley M, Fitz Y, Correa-Araujo R, Banks SM, Leppla SH, Eichacker PQ. Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol 2004;286:R699-R709. (Pubitemid 38375001)
42. Sweeney DA, Cui X, Solomon SB, Vitberg DA, Migone TS, Scher D, Danner RL, Natanson C, Subramanian GM, Eichacker PQ. Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J Infect Dis 2010;202:1885-1896.
43. Bolcome RE III, Chan J. Constitutive mek1 activation rescues anthrax lethal toxin-induced vascular effects in vivo. Infect Immun 2010;78:5043-5053.
44. Gozes Y, Moayeri M, Wiggins JF, Leppla SH. Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect Immun 2006;74:1266-1272. (Pubitemid 43185566)
45. Rolando M, Stefani C, Flatau G, Auberger P, Mettouchi A, Mhlanga M, Rapp U, Galmiche A, Lemichez E. Transcriptome dysregulation by anthrax lethal toxin plays a key role in induction of human endothelial cell cytotoxicity. Cell Microbiol 2010;12:891-905.
46. Watson LE, Mock J, Lal H, Lu G, Bourdeau RW, Tang WJ, Leppla SH, Dostal DE, Frankel AE. Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Front Biosci 2007;12:4670-4675.
47. Kandadi MR, Hua Y, Ma H, Li Q, Kuo SR, Frankel AE, Ren J. Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a nadph oxidase-dependent mechanism. PLoS ONE 2010;5:e13335.
48. Li Y, Cui X, Su J, Haley M, Macarthur H, Sherer K, Moayeri M, Leppla SH, Fitz Y, Eichacker PQ. Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats. Crit Care Med 2009;37:1348-1354.
49. Griffith TM, Taylor HJ. Cyclic amp mediates edhf-type relaxations of rabbit jugular vein. Biochem Biophys Res Commun 1999;263:52-57. (Pubitemid 29443638)
50. Stehlik J, Movsesian MA. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Expert Opin Investig Drugs 2006;15:733-742.
51. Borer JS. Drug insight: if inhibitors as specific heart-rate-reducing agents. Nat Clin Pract Cardiovasc Med 2004;1:103-109. (Pubitemid 40823707)
52. Hicks CW, Li Y, Okugawa S, Solomon SB, Moayeri M, Leppla SH, Mohanty A, Subramanian GM, Mignone TS, Fitz Y, Cui X, Eichacker PQ. Anthrax edema toxin has camp-mediated stimulatory effects and high dose lethal toxin has depressant effects in an isolated perfused rat heart model. Am J Physiol Heart Circ Physiol 2011;300:H1108-H1118.
53. Chakrabarty K, Wu W, Booth JL, Duggan ES, Nagle NN, Coggeshall KM, Metcalf JP. Human lung innate immune response to bacillus anthracis spore infection. Infect Immun 2007;75:3729-3738. (Pubitemid 47206270)
54. Stearns-Kurosawa DJ, Lupu F, Taylor FB Jr, Kinasewitz G, Kurosawa S. Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am J Pathol 2006;169:433-444. (Pubitemid 44156306)
55. Popov SG, Villasmil R, Bernardi J, Grene E, Cardwell J, Popova T, Wu A, Alibek D, Bailey C, Alibek K. Effect of bacillus anthracis lethal toxin on human peripheral blood mononuclear cells. FEBS Lett 2002;527:211-215. (Pubitemid 35253867)
56. Triantafilou M, Uddin A, Maher S, Charalambous N, Hamm TS, Alsumaiti A, Triantafilou K. Anthrax toxin evades toll-like receptor recognition, whereas its cell wall components trigger activation via tlr2/6 heterodimers. Cell Microbiol 2007;9:2880-2892. (Pubitemid 350066572)
57. Langer M, Malykhin A, Maeda K, Chakrabarty K, Williamson KS, Feasley CL, West CM, Metcalf JP, Coggeshall KM. Bacillus anthracis peptidoglycan stimulates an inflammatory response in monocytes through the p38 mitogen-activated protein kinase pathway. PLoS ONE 2008;3:e3706.
58. Hsu LC, Ali SR, McGillivray S, Tseng PH, Mariathasan S, Humke EW, Eckmann L, Powell JJ, Nizet V, Dixit VM, et al. A nod2-nalp1 complex mediates caspase-1-dependent il-1beta secretion in response to bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci USA 2008;105:7803-7808. (Pubitemid 351872719)
59. Cui X, Su J, Li Y, Shiloach J, Solomon S, Kaufman JB, Mani H, Fitz Y, Weng J, Altaweel L, et al. Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model. Intensive Care Med 2010;36:148-156.
60. Popov SG, Popova TG, Hopkins S, Weinstein RS, MacAfee R, Fryxell KJ, Chandhoke V, Bailey C, Alibek K. Effective antiprotease-antibiotic treatment of experimental anthrax. BMC Infect Dis 2005;5:25.
61. Chung MC, Jorgensen SC, Popova TG, Tonry JH, Bailey CL, Popov SG. Activation of plasminogen activator inhibitor implicates protease inha in the acute-phase response to bacillus anthracis infection. J Med Microbiol 2009;58:737-744.
62. Centers for Disease Control and Prevention (CDC). Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 2001;50:889-893.
63. Centers for Disease Control and Prevention (CDC). Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001;50:909-919.
64. Morse S, Kellogg R, Perry S. Detecting biothreat agents: the laboratory response network. ASM News 2003;69:433.
65. Center for Infectious Disease Research & Policy. Anthrax: current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis. May 25, 2011 [accessed 2011 June 13]. Available from: http://www.cidrap.umn.edu/cidrap/content/bt/anthrax/biofacts/ anthraxfactsheet.html.
66. Swartz MN. Recognition and management of anthrax: an update. N Engl J Med 2001;345:1621-1626.
67. Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of clostridium perfringens. Antimicrob Agents Chemother 1987;31:213-218. (Pubitemid 17011240)
68. Anaraki S, Addiman S, Nixon G, Krahe D, Ghosh R, Brooks T, Lloyd G, Spencer R, Walsh A, McCloskey B, et al. Investigations and control measures following a case of inhalation anthrax in east london in a drum maker and drummer, October 2008. Euro Surveill 2008;13:19076.
69. Centers for Disease Control and Prevention (CDC). CDC emergency preparedness and response site [accessed 2011 July 7]. Available from: www.bt.cdc.gov/.
70. Hewetson JF, Little SF, Ivins BE, Johnson WM, Pittman PR, Brown JE, Norris SL, Nielsen CJ. An in vivo passive protection assay for the evaluation of immunity in ava-vaccinated individuals. Vaccine 2008;26:4262-4266.
71. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009;361:135-144.
72. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL, Zaki S, Popovic T, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the united states. Emerg Infect Dis 2001;7:933-944. (Pubitemid 33115771)
73. Doust JY, Sarkarzadeh A, Kavoossi K. Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest 1968;53:773-774.
74. Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis 2005;5:287-295. (Pubitemid 40602248)
75. Lanska DJ. Anthrax meningoencephalitis. Neurology 2002;59:327-334. (Pubitemid 34857923)
76. Parcell BJ, Wilmshurst AD, France AJ, Motta L, Brooks T, Olver WJ. Injection anthrax causing compartment syndrome and necrotising fasciitis. J Clin Pathol 2011;64:95-96.
77. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis 2008;14:07-0969.
78. Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in response to terrorism: supplemental recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2002;51:1024-1026.
79. Anthrax vaccine. Med Lett Drugs Ther 1998;40:52-53.
80. Baillie L. The development of new vaccines against bacillus anthracis. J Appl Microbiol 2001;91:609-613. (Pubitemid 32948383)
81. Bartlett JG, Inglesby TV Jr, Borio L. Management of anthrax. Clin Infect Dis 2002;35:851-858.
82. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239-1243. (Pubitemid 23115626)
83. Wright JG, Quinn CP, Shadomy S, Messonnier N. Use of anthrax vaccine in the United States: recommendations of the advisory committee on immunization practices (ACIP), 2009. MMWR Recomm Rep 2010;59:1-30.
84. Wood BJ, DeFranco B, Ripple M, Topiel M, Chiriboga C, Mani V, Barry K, Fowler D, Masur H, Borio L. Inhalational anthrax: radiologic and pathologic findings in two cases. AJR Am J Roentgenol 2003;181:1071-1078. (Pubitemid 37151793)
85. Jallali N, Hettiaratchy S, Gordon AC, Jain A. The surgical management of injectional anthrax. J Plast Reconstr Aesthet Surg 2011;64:276-277.